Literature DB >> 8443965

Serum markers of T cell activation in relapses of Wegener's granulomatosis.

C A Stegeman1, J W Tervaert, M G Huitema, C G Kallenberg.   

Abstract

Levels of soluble IL-2 receptor (sIL-2R), soluble CD4 (sCD4) and CD8 (sCD8) were measured by sandwich ELISA as markers for T cell activation in serial serum samples from 16 patients showing 18 histologically proven relapses of Wegener's granulomatosis (WG). Levels of sIL-2R increased from 1065 U/ml (median, range 373-2345 U/ml) 6 months before the relapse to 1684 U/ml (median, range 486-3404 U/ml) at the moment of relapse for the whole group (P = 0.10). The eight major relapses showed a profound rise in sIL-2R levels, from 1008 U/ml (median, range 686-1553 U/ml) 6 months before the relapse, to 1994 U/ml (median, range 1469-3404 U/ml) at the moment of relapse (P < 0.01). The levels of sIL-2R at the moment of relapse were significantly higher at the eight major relapses than at the time of the 10 minor relapses (P < 0.05). Minor relapses were not accompanied by a significant rise in sIL-2R levels. Titres of antineutrophil cytoplasmic antibodies (ANCA) rose by two or more titresteps or from negative to positive in 15/18 patients during the 6 months period before the relapse. In all seven cases with both a rise of the ANCA titre and an at least 25% increase in sIL-2R levels, the rise in ANCA preceded the rise in sIL-2R by at least 1 month. The level of sIL-2R at the moment of relapse correlated with the level of C-reactive protein (r = 0.488, P < 0.05) and with the disease activity score (r = 0.824, P < 0.002). There were no significant changes in levels of sCD4 or sCD8, although the levels of sCD4 tended to be higher at the time of major relapses. We conclude that major relapses of Wegener's granulomatosis are accompanied by systemic T cell activation. T cell activation, however, does not appear to precede the rise in ANCA titre.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443965      PMCID: PMC1554716          DOI: 10.1111/j.1365-2249.1993.tb05918.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.

Authors:  A S Fauci; B Haynes; P Katz
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

2.  An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro.

Authors:  D L Nelson; L A Rubin; C C Kurman; M E Fritz; B Boutin
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

3.  Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration.

Authors:  C R Hind; C G Winearls; C M Lockwood; A J Rees; M B Pepys
Journal:  Clin Nephrol       Date:  1984-06       Impact factor: 0.975

4.  Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers.

Authors:  G N Gephardt; M Ahmad; R R Tubbs
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

5.  Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes.

Authors:  W Holter; C K Goldman; L Casabo; D L Nelson; W C Greene; T A Waldmann
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

6.  Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.

Authors:  S Sawada; S Sugai; S Iijima; M Takei; E Paredes; T Hayama; S Nishinarita; Y Hosokawa; T Horie; T Obara
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

7.  Soluble interleukin-2 receptors in systemic lupus erythematosus.

Authors:  R E Wolf; W G Brelsford
Journal:  Arthritis Rheum       Date:  1988-06

8.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Interleukin-2 receptor levels are increased in blood of heart transplant patients during infections.

Authors:  V Stolc; J R Krause
Journal:  Diagn Clin Immunol       Date:  1987
View more
  28 in total

Review 1.  Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Authors:  A D Salama
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

Review 2.  Immunopathological aspects of systemic vasculitis.

Authors:  I M Bajema; E C Hagen; F Ferrario; E de Heer; J A Bruijn
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

5.  Detecting T Cell Activation Using a Varying Dimension Bayesian Model.

Authors:  Zicheng Hu; Jessica N Lancaster; Lauren I R Ehrlich; Peter Müller
Journal:  J Appl Stat       Date:  2017-02-16       Impact factor: 1.404

6.  Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis.

Authors:  Kouichi Hirayama; Takashi Ishizu; Homare Shimohata; Yasunori Miyamoto; Tomoko Kakita; Miho Nagai; Yujiro Ogawa; Shogo Fujita; Aki Hirayama; Kunihiro Yamagata; Masaki Kobayashi; Akio Koyama
Journal:  Clin Exp Nephrol       Date:  2009-10-07       Impact factor: 2.801

Review 7.  Assessment of disease activity in systemic vasculitis.

Authors:  W Y Tse; P Cockwell; C O Savage
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

8.  An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).

Authors:  Carol A Langford; Paul A Monach; Ulrich Specks; Philip Seo; David Cuthbertson; Carol A McAlear; Steven R Ytterberg; Gary S Hoffman; Jeffrey P Krischer; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2013-12-09       Impact factor: 19.103

9.  Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.

Authors:  P E Spronk; E J ter Borg; M G Huitema; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

10.  CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients.

Authors:  Laurence Ordonez; Isabelle Bernard; Fatima-Ezzahra L'faqihi-Olive; Jan Willem Cohen Tervaert; Jan Damoiseaux; Abdelhadi Saoudi
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.